Description
Product Overview: KLOW Blend (KPV / BPC-157 / TB-500 / GHK-Cu)
The KLOW Blend is a powerful 4-in-1 regenerative research complex combining KPV, BPC-157, TB-500, and GHK-Cu (Copper Peptide). Engineered for multi-layered tissue reconstruction, this formulation integrates the targeted cytoprotective and VEGFR2 angiogenic signaling of BPC-157, the systemic actin sequestration and cellular motility of TB-500, the NF-$\kappa$B nuclear anti-inflammatory blockade of KPV, and the extracellular matrix (ECM) remodeling and gene-modulating properties of GHK-Cu. Together, these compounds form a comprehensive matrix for studying advanced musculoskeletal, mucosal, and dermal repair.
Primary Research Applications & Reasons for Study
- Extracellular Matrix (ECM) Synthesis: Utilizing GHK-Cu to stimulate Type I & III collagen, elastin, and glycosaminoglycan production while regulating matrix metalloproteinases (MMPs).
- Dual-Level Angiogenesis & Motility: Combining VEGFR2 pathway activation (BPC-157) with actin polymerization dynamics (TB-500) to accelerate blood vessel formation in avascular tissues.
- Targeted & Systemic Cytokine Suppression: Blocking NF-$\kappa$B nuclear translocation (KPV) to downregulate pro-inflammatory cascades ($\text{TNF-}\alpha$, $\text{IL-6}$, $\text{IL-1}\beta$) without immune suppression.
- Musculoskeletal & Dermal Reconstruction: Evaluating rapid recovery rates in tendon transection, ligament disruption, wound re-epithelialization, and joint cartilage degradation models.
Expected Research Results & Timeline Metrics
-
Phase 1 / Days 1–5
Acute Anti-Inflammatory Response: Immediate nuclear entry of KPV, suppression of inflammatory cytokine surges, and early endothelial cell recruitment to damaged tissue sites. -
Phase 2 / Weeks 1–3
Microvascular Growth & Fibroblast Proliferation: Statistically significant increases in capillary sprouting (BPC-157/TB-500), rapid collagen deposition, and restoration of skin barrier tight junctions. -
Phase 3 / Weeks 4–8
Complete Matrix Alignment & Scar Minimization: Advanced extracellular matrix remodeling (GHK-Cu), restoration of tensile load capacity in tendons/ligaments, and minimal fibrous adhesion formation.
Key Research Benefits
- Quad-Action Synergistic Matrix: Combines four of the most widely researched tissue-repair peptides into a single, highly convenient laboratory preparation.
- Full-Spectrum Repair Architecture: Addresses every critical stage of tissue recovery: inflammation control (KPV), local signaling (BPC-157), cell migration (TB-500), and structural remodeling (GHK-Cu).
- Gene Modulation & Anti-Fibrotic Focus: Up- and down-regulates hundreds of human genes associated with wound healing while suppressing non-functional scar tissue.
- Cross-Tissue Versatility: Ideal for investigating skin aging/damage, gastrointestinal lining repair, and complex musculoskeletal injury models.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.